Lunch Symposia

Wednesday, 19 April, 13:30-14:30 - Abbott Point of Care Division

ACT testing -When there’s no room for doubt

Chair: Prof. Florian Falter (UK)

  • Can we bring the lab to the OR? -  Dr. Evelien Kemna (Nederland)
  • ACT 2017 -  Dr. med. Daniel Dirkmann (Germany)
  • Time to ACT? -  Prof. Florian Falter (UK)

 

Wednesday, 19 April, 13:30-14:30 - Edwards Lifesciences

PAC Technology – Past, Present and Future

Moderator: Prof. Dr. Steffen Rex (Leuven, Belgium)

  • “The role of oxygen delivery and consumption for the outcome of high risk surgical patients – Shoemaker’s theorem revisited”
    Prof. Dr. Michael Sander (Berlin, Germany)
  • “Diagnosis of right ventricular failure and RV outflow tract obstruction with the PAC”
    Prof. Dr. André Denault (Montreal, Canada)
  • “The PAC in 2017 – new clinical data on its safety and efficacy in cardiac surgery”
    Dr. Andy Shaw (Nashville, USA)

 

Thursday, 20 April, 13:30-14:30 - Medtronic

INTRA-PROCEDURAL MANAGEMENT TO IMPROVE PATIENT OUTCOMES

  • “Enhanced Recovery Pathway: New Model for Perioperative Health Care”
    Speaker: TJ Gan, M.D. (USA)
  • “Goal Directed Perfusion Trial”
    Speaker: Dott. Tommaso Aloisio, (Italy)
  • “The Importance of NIRS and the Differences in Algorithm to Optimize Patient Outcomes”
    Speaker: Prof. Julien Amour, (France)

 

Thursday, 20 April, 13:30-14:30 - Orion Corp.

Pre-, Peri-, and Post-operative use of levosimendan: the LEVO-CTS, CHEETAH and LICORN trials in the eye of clinical practice

Chairs: Matthias Heringlake (Germany), Fabio Guarracino (Italy), Sven-Erik Ricksten (Sweden)

Levosimendan, a cardioprotective inodilator, was developed as a treatment for acute heart failure and is used. In this symposium, the investigators of three recent clinical trials on levosimendan in the cardiac surgery settings will describe and discuss their results. Prof.Cholley (Paris, France) will present the LICORN trial of peri-operative use of levosimendan, Prof. Landoni (Milan, Italy) the CHEETAH trial of post-operative use of levosimendan, and Prof. Heringlake (Lübeck, Germany) the LEVO-CTS trial on pre-operative use of levosimendan. Prof. Guarracino (Pisa, Italy) and Ricksten (Gotenburg, Sweden) will join the discussion in a final panel debate.

 

Friday, 21 April, 13:30-14:30 - CSL Behring

Bleeding: a challenge in cardiovascular surgery

Chairs: Donat Spahn (Switzerland), Kai Zacharowski (Germany)

  • Strategies to treat bleeding - Marco Ranucci (Italy)
  • Haemostatic therapy in cardiac surgery - Arno Nierich (Netherlands)
  • Management of bleeding in patients on ECMO - Dirk Lunz (Germany)

 

Friday, 21 April, 13:30 - 14:30 Nordic Pharma

WHAT PLACE DOES APROTININ HAVE IN FUTURE CLINICAL PRACTICE?

Chair: Prof. Christian von Heymann (Germany)

  • Aprotinin clinical evidences: do we really need it? Prof. Christian von Heymann (Germany)
  • An unprecedented come back! Dr. David Royston (United Kingdom)
  • Aprotinin today: sharing of experience Prof. Jan Van der Linden (Sweden)